Semirara Mining and Power Corporation (PSE:SCC)

Verve Therapeutics Income Statement

Financials in millions PHP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	63,277	65,194	76,960	91,129	52,424	28,250
Revenue Growth (YoY)	-15.27%	-15.29%	-15.55%	73.83%	85.57%	-36.16%
Cost of Revenue	35,384	34,631	34,165	30,802	26,693	19,983
Gross Profit	27,893	30,564	42,796	60,327	25,731	8,268
Selling, General & Admin	2,438	2,258	2,043	1,891	1,594	1,417
Other Operating Expenses	6,520	7,420	11,688	16,759	7,144	2,503
Operating Expenses	9,079	9,799	13,808	18,751	8,821	4,012
Operating Income	18,815	20,765	28,988	41,576	16,910	4,255
Interest Expense	-192	-249.24	-453.38	-683.51	-873.38	-1,050
Interest & Investment Income	684.75	885.26	1,183	410.58	20.6	45.63
Earnings From Equity Investments	-68.98	10.72	-	-	-	-
Currency Exchange Gain (Loss)	-111.67	-113.6	-175.81	1,004	339.6	154.69
Other Non Operating Income (Expenses)	361.5	316.67	584.18	87.35	150.5	167.55
EBT Excluding Unusual Items	19,488	21,615	30,126	42,394	16,547	3,574
Gain (Loss) on Sale of Assets	5.86	5.86	-	0.42	-1.99	67
Asset Writedown	-	-	-76.09	-171.77	-	-258.43
Other Unusual Items	-	-	-	-	-	37.24
Pretax Income	19,681	21,807	30,082	42,223	16,545	3,419
Income Tax Expense	2,238	2,177	2,148	2,352	345.12	132.6
Net Income	17,442	19,630	27,933	39,871	16,200	3,287
Net Income to Common	17,442	19,630	27,933	39,871	16,200	3,287
Net Income Growth	-31.44%	-29.73%	-29.94%	146.12%	392.89%	-66.04%
Shares Outstanding (Basic)	4,256	4,251	4,251	4,251	4,251	4,251
Shares Outstanding (Diluted)	4,256	4,251	4,251	4,251	4,251	4,251
Shares Change (YoY)	0.20%	-	-	-	-	-
EPS (Basic)	4.10	4.62	6.57	9.38	3.81	0.77
EPS (Diluted)	4.10	4.62	6.57	9.38	3.81	0.77
EPS Growth	-31.58%	-29.73%	-29.94%	146.12%	392.89%	-66.04%
Free Cash Flow	16,754	22,175	31,580	36,471	17,415	4,341
Free Cash Flow Per Share	3.94	5.22	7.43	8.58	4.10	1.02
Dividend Per Share	1.250	1.250	1.500	1.800	1.500	1.250
Dividend Growth	-16.67%	-16.67%	-16.67%	20.00%	20.00%	-
Gross Margin	44.08%	46.88%	55.61%	66.20%	49.08%	29.27%
Operating Margin	29.73%	31.85%	37.67%	45.62%	32.26%	15.06%
Profit Margin	27.57%	30.11%	36.30%	43.75%	30.90%	11.63%
Free Cash Flow Margin	26.48%	34.01%	41.03%	40.02%	33.22%	15.37%
EBITDA	26,375	28,075	36,033	47,395	23,287	10,428
EBITDA Margin	41.68%	43.06%	46.82%	52.01%	44.42%	36.91%
D&A For EBITDA	7,560	7,310	7,045	5,819	6,378	6,173
EBIT	18,815	20,765	28,988	41,576	16,910	4,255
EBIT Margin	29.73%	31.85%	37.67%	45.62%	32.26%	15.06%
Effective Tax Rate	11.37%	9.98%	7.14%	5.57%	2.09%	3.88%
Revenue as Reported	63,277	65,194	76,960	91,129	52,424	28,250

Source: S&P Global Market Intelligence. Standard template. Financial Sources.